FDA Sets A Fast Pace Of Novel Approvals In First Half, But That's Likely To Slow
By
Bridget Silverman / Email the Author / Pharmaceutical Approvals Monthly July 2011, Vol. 16, No. 7
New Drug Reviews / Word Count: 1528 / Article # 06110701024
Executive Summary
A sparsely populated user fee calendar for the remainder of 2011 likely precludes a repeat of FDA’s stunning approval performance in the first half of this year. Still, with 20 approvals of new molecular entities and novel biologics during those first six months, the agency is all but assured of one of its best years in a decade – at the least.
$85.00
Buy Now
For $85.00, purchase this 1528-word article and receive immediate online access. 100% Satisfaction Guarantee.
Already a Subscriber?
Log in for complete access.
Log In
Questions?
Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.